September 17, 2017
NEW ORLEANS — Data presented here indicated efficacy and safety of Mydayis, a once-daily mixed salts of a single-entity amphetamine product, for ADHD in adults.
“It was very important for us to pull all the studies together that we’ve studied in the adult population. The first one is the efficacy and safety poster comparing Mydayis [Shire] to placebo in three of our randomized controlled studies and one long-term study to allow everyone to assess the short-term efficacy and the long-term 52-week efficacy of Mydayis compared to placebo,” Manisha Madhoo, MD, vice president, Global Medical Affairs, Neuroscience, Shire, told Healio.com/Psychiatry. “The conclusions of these studies are that ... Mydayis is significantly clinically superior to placebo in the [ADHD Rating Scale] and [Clinical Global Impressions-Improvement]. In the global clinical function scale, Mydayis compared to placebo is superior.”